<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378833</url>
  </required_header>
  <id_info>
    <org_study_id>0524A-054</org_study_id>
    <secondary_id>2006_529</secondary_id>
    <nct_id>NCT00378833</nct_id>
  </id_info>
  <brief_title>Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)</brief_title>
  <official_title>A Worldwide, Multicenter, Double-Blind, Parallel Study to Evaluate the Tolerability of MK0524A Versus Niacin Extended-Release</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This is a 16-week clinical trial in lipid clinic patients for whom niacin therapy is
      appropriate to evaluate the tolerability of MK0524A versus niacin extended-release. There
      will be 6 scheduled clinic visits and 2 treatment groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Flushing Severity Score (GFSS) over 16 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety/tolerability</measure>
  </secondary_outcome>
  <enrollment type="Actual">1300</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Hyperlipidemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>niacin (+) laropiprant</intervention_name>
    <description>Duration of Treatment: 18 Weeks</description>
    <other_name>MK0524A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>niacin</intervention_name>
    <description>Duration of Treatment: 18 Weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is an appropriate candidate for niacin therapy (at risk for heart disease) and
             triglycerides &lt; 500 mg/dL

        Exclusion Criteria:

          -  Patients with a history of any cardiovascular event directly linked to atherosclerosis
             with a low density lipoprotein-cholesterol (LDL-C) &gt;/= 130 mg/dL and/or not on a
             statin

          -  Patients with diabetes and LDL-C &gt;/= 130 mg/dL. Patients with &gt;/= 2 heart disease risk
             factors and LDL-C &gt;/= 160 mg/dL.

          -  Patients who have had a cardiovascular event (e.g., heart attack, stroke) within the
             previous 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 1;104(1):74-81. doi: 10.1016/j.amjcard.2009.02.047.</citation>
    <PMID>19576324</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2006</study_first_submitted>
  <study_first_submitted_qc>September 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2006</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Hypercholesterolemia or Mixed Hyperlipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

